NR 565 | Advanced Pharmacology
NR 565 Advanced Pharmacology Final
Comprehensive Examination 2026/2027
| Verified Questions
NR 565 | Advanced Pharmacology | University-Level Advanced Practice Nursing Students
100 Verified Questions | 4 Core Domains | Academic Year 2026/2027
Prepared by
NR 565 | Advanced Pharmacology
Final Comprehensive Examination Actual Exam | Academic Year 2026/2027
NR 565 Advanced Pharmacology Final Comprehensive Examination 2026/2027 | Verified Questions
,INTRODUCTION
This final comprehensive examination contains exactly 100 original verified questions designed for
University-Level Advanced Practice Nursing students enrolled in NR 565 Advanced Pharmacology. The
questions are distributed equally across four core domains: Pharmacologic Principles, Pharmacokinetics,
and Prescribing Guidelines (25 questions), Cardiovascular and Respiratory Pharmacology (25 questions),
Neurological, Psychiatric, and Pain Management Pharmacology (25 questions), and Endocrine,
Gastrointestinal, and Musculoskeletal Pharmacology (25 questions). Content is original and aligned with
the official NR 565 course objectives for the Academic Year 2026/2027, reinforcing foundational
advanced pharmacology knowledge, clinical prescribing logic, and mechanistic understanding required
for actual exam readiness and clinical proficiency.
ACTUAL QUESTIONS
Domain 1: Pharmacologic Principles, Pharmacokinetics, and Prescribing Guidelines
Question 1. A patient with significant hepatic impairment is prescribed an oral medication
that undergoes extensive first-pass metabolism. Which adjustment is most appropriate?
A. Increase the dose because first-pass effect is reduced
B. Decrease the dose because oral bioavailability will increase
C. Maintain the standard dose because renal clearance compensates
D. Switch to an intravenous formulation only if creatinine clearance falls below 30 mL/min
Correct Answer: B
Rationale: Hepatic impairment reduces first-pass metabolism of high-extraction drugs, increasing oral
bioavailability and the risk of toxicity; dose reduction is therefore required.
Question 2. Which parameter is the primary determinant of the time required to reach
steady-state plasma concentration during continuous intravenous infusion?
A. Volume of distribution
B. Clearance
C. Bioavailability
D. Elimination half-life
Correct Answer: D
Rationale: Steady state is approached after approximately four to five half-lives regardless of dose or
infusion rate; elimination half-life therefore governs time to steady state.
Question 3. A highly protein-bound drug is given to a patient with severe
hypoalbuminemia. What change in free drug concentration is expected?
A. Increased free fraction and potentially increased pharmacologic effect
B. Decreased free fraction due to compensatory receptor upregulation
C. No change because total drug concentration remains constant
D. Decreased free fraction because hepatic albumin synthesis increases
Correct Answer: A
Rationale: Hypoalbuminemia reduces available binding sites, elevating the unbound fraction that
drives both therapeutic effect and toxicity risk.
Question 4. Which cytochrome P450 enzyme metabolizes the largest proportion of
currently prescribed drugs and is most frequently implicated in drug–drug interactions?
A. CYP2C19
B. CYP2D6
C. CYP3A4
D. CYP1A2
NR 565 Advanced Pharmacology Final Comprehensive Examination 2026/2027 | Verified Questions
, Correct Answer: C
Rationale: CYP3A4 is responsible for the oxidative metabolism of more than half of therapeutic drugs
and is the enzyme most commonly involved in clinically significant interactions.
Question 5. A patient taking a narrow-therapeutic-index drug develops toxicity after
starting a potent CYP3A4 inhibitor. Which pharmacokinetic process has been altered?
A. Absorption rate
B. Metabolic clearance
C. Renal excretion
D. Plasma protein binding
Correct Answer: B
Rationale: CYP3A4 inhibition reduces metabolic clearance of the substrate, elevating plasma
concentrations and precipitating toxicity.
Question 6. Which statement correctly describes zero-order elimination kinetics?
A. A constant fraction of drug is eliminated per unit time
B. Elimination rate is proportional to plasma concentration
C. Half-life remains constant across the dosing range
D. A constant amount of drug is eliminated per unit time
Correct Answer: D
Rationale: Zero-order kinetics eliminate a fixed quantity of drug per unit time, independent of
concentration, as seen with phenytoin and ethanol at therapeutic doses.
Question 7. For a drug that follows first-order kinetics, doubling the dose will
approximately double which steady-state parameter?
A. Plasma concentration
B. Elimination half-life
C. Clearance
D. Volume of distribution
Correct Answer: A
Rationale: Under first-order conditions, steady-state concentration is directly proportional to dosing
rate; half-life, clearance, and volume of distribution remain unchanged.
Question 8. A medication is described as having a large volume of distribution (Vd > 100
L). What does this indicate?
A. The drug is largely confined to plasma
B. The drug undergoes extensive first-pass metabolism
C. The drug is extensively distributed into extravascular tissues
D. The drug is highly water-soluble and remains in extracellular fluid
Correct Answer: C
Rationale: A large Vd indicates that most of the drug has left the plasma compartment and entered
tissues, typically because of high lipid solubility or tissue binding.
Question 9. Which factor most strongly influences the oral bioavailability of a lipophilic
drug?
A. Gastric emptying time alone
B. Extent of first-pass hepatic metabolism
C. Renal tubular secretion
D. Plasma protein binding percentage
Correct Answer: B
Rationale: For lipophilic compounds, extensive first-pass extraction by the liver (and sometimes gut
wall) is the dominant determinant of oral bioavailability.
NR 565 Advanced Pharmacology Final Comprehensive Examination 2026/2027 | Verified Questions
NR 565 Advanced Pharmacology Final
Comprehensive Examination 2026/2027
| Verified Questions
NR 565 | Advanced Pharmacology | University-Level Advanced Practice Nursing Students
100 Verified Questions | 4 Core Domains | Academic Year 2026/2027
Prepared by
NR 565 | Advanced Pharmacology
Final Comprehensive Examination Actual Exam | Academic Year 2026/2027
NR 565 Advanced Pharmacology Final Comprehensive Examination 2026/2027 | Verified Questions
,INTRODUCTION
This final comprehensive examination contains exactly 100 original verified questions designed for
University-Level Advanced Practice Nursing students enrolled in NR 565 Advanced Pharmacology. The
questions are distributed equally across four core domains: Pharmacologic Principles, Pharmacokinetics,
and Prescribing Guidelines (25 questions), Cardiovascular and Respiratory Pharmacology (25 questions),
Neurological, Psychiatric, and Pain Management Pharmacology (25 questions), and Endocrine,
Gastrointestinal, and Musculoskeletal Pharmacology (25 questions). Content is original and aligned with
the official NR 565 course objectives for the Academic Year 2026/2027, reinforcing foundational
advanced pharmacology knowledge, clinical prescribing logic, and mechanistic understanding required
for actual exam readiness and clinical proficiency.
ACTUAL QUESTIONS
Domain 1: Pharmacologic Principles, Pharmacokinetics, and Prescribing Guidelines
Question 1. A patient with significant hepatic impairment is prescribed an oral medication
that undergoes extensive first-pass metabolism. Which adjustment is most appropriate?
A. Increase the dose because first-pass effect is reduced
B. Decrease the dose because oral bioavailability will increase
C. Maintain the standard dose because renal clearance compensates
D. Switch to an intravenous formulation only if creatinine clearance falls below 30 mL/min
Correct Answer: B
Rationale: Hepatic impairment reduces first-pass metabolism of high-extraction drugs, increasing oral
bioavailability and the risk of toxicity; dose reduction is therefore required.
Question 2. Which parameter is the primary determinant of the time required to reach
steady-state plasma concentration during continuous intravenous infusion?
A. Volume of distribution
B. Clearance
C. Bioavailability
D. Elimination half-life
Correct Answer: D
Rationale: Steady state is approached after approximately four to five half-lives regardless of dose or
infusion rate; elimination half-life therefore governs time to steady state.
Question 3. A highly protein-bound drug is given to a patient with severe
hypoalbuminemia. What change in free drug concentration is expected?
A. Increased free fraction and potentially increased pharmacologic effect
B. Decreased free fraction due to compensatory receptor upregulation
C. No change because total drug concentration remains constant
D. Decreased free fraction because hepatic albumin synthesis increases
Correct Answer: A
Rationale: Hypoalbuminemia reduces available binding sites, elevating the unbound fraction that
drives both therapeutic effect and toxicity risk.
Question 4. Which cytochrome P450 enzyme metabolizes the largest proportion of
currently prescribed drugs and is most frequently implicated in drug–drug interactions?
A. CYP2C19
B. CYP2D6
C. CYP3A4
D. CYP1A2
NR 565 Advanced Pharmacology Final Comprehensive Examination 2026/2027 | Verified Questions
, Correct Answer: C
Rationale: CYP3A4 is responsible for the oxidative metabolism of more than half of therapeutic drugs
and is the enzyme most commonly involved in clinically significant interactions.
Question 5. A patient taking a narrow-therapeutic-index drug develops toxicity after
starting a potent CYP3A4 inhibitor. Which pharmacokinetic process has been altered?
A. Absorption rate
B. Metabolic clearance
C. Renal excretion
D. Plasma protein binding
Correct Answer: B
Rationale: CYP3A4 inhibition reduces metabolic clearance of the substrate, elevating plasma
concentrations and precipitating toxicity.
Question 6. Which statement correctly describes zero-order elimination kinetics?
A. A constant fraction of drug is eliminated per unit time
B. Elimination rate is proportional to plasma concentration
C. Half-life remains constant across the dosing range
D. A constant amount of drug is eliminated per unit time
Correct Answer: D
Rationale: Zero-order kinetics eliminate a fixed quantity of drug per unit time, independent of
concentration, as seen with phenytoin and ethanol at therapeutic doses.
Question 7. For a drug that follows first-order kinetics, doubling the dose will
approximately double which steady-state parameter?
A. Plasma concentration
B. Elimination half-life
C. Clearance
D. Volume of distribution
Correct Answer: A
Rationale: Under first-order conditions, steady-state concentration is directly proportional to dosing
rate; half-life, clearance, and volume of distribution remain unchanged.
Question 8. A medication is described as having a large volume of distribution (Vd > 100
L). What does this indicate?
A. The drug is largely confined to plasma
B. The drug undergoes extensive first-pass metabolism
C. The drug is extensively distributed into extravascular tissues
D. The drug is highly water-soluble and remains in extracellular fluid
Correct Answer: C
Rationale: A large Vd indicates that most of the drug has left the plasma compartment and entered
tissues, typically because of high lipid solubility or tissue binding.
Question 9. Which factor most strongly influences the oral bioavailability of a lipophilic
drug?
A. Gastric emptying time alone
B. Extent of first-pass hepatic metabolism
C. Renal tubular secretion
D. Plasma protein binding percentage
Correct Answer: B
Rationale: For lipophilic compounds, extensive first-pass extraction by the liver (and sometimes gut
wall) is the dominant determinant of oral bioavailability.
NR 565 Advanced Pharmacology Final Comprehensive Examination 2026/2027 | Verified Questions
